Avacta Group plc (LSE:AVCT) has shared encouraging clinical data from its ongoing Phase 1b trial of AVA6000 (FAP-Dox), reporting a partial tumor response in a patient with metastatic salivary gland cancer. This marks a significant milestone in the study’s dose expansion phase and highlights the potential of AVA6000 as a targeted treatment option for a rare cancer type with limited therapeutic alternatives.
The result is particularly noteworthy given the absence of a widely accepted standard of care for salivary gland cancer, underlining the importance of developing innovative treatments. Avacta plans to release full results from the earlier Phase 1a portion of the trial later in 2025. The company is also expected to provide further updates on its clinical programs and corporate strategy during its upcoming Annual General Meeting.
About Avacta Group plc
Avacta is a clinical-stage biotechnology company advancing a new class of precision oncology therapies. Through its proprietary pre|CISION® platform, the company is developing tumor-targeted drug candidates that activate potent chemotherapy agents within the tumor microenvironment, helping to minimize harm to healthy tissues. Avacta’s pipeline includes both pre|CISION® peptide drug conjugates and Affimer®-based drug conjugates, offering potential advantages over conventional antibody drug approaches in cancer treatment.
Leave a Reply